Submission Details
Molecule(s):
CS(=O)(=O)Nc1cc2cncc(NC(=O)[C@@H]3CN(S(=O)(=O)CC4(C#N)CC4)Cc4ccc(Cl)cc43)c2cc1F
CNC(=O)CN1Cc2ccc(Cl)cc2[C@H](C(=O)Nc2cncc3cc(NS(C)(=O)=O)c(F)cc23)C1
CNC(=O)CN1C[C@@H](C(=O)Nc2cncc3cc(NS(C)(=O)=O)c(F)cc23)c2cc(Cl)ccc2C1=O
CS(=O)(=O)Nc1cc2cncc(N3CC[C@]4(CN(S(=O)(=O)CC5(C#N)CC5)Cc5ccc(Cl)cc54)C3=O)c2cc1F
CNC(=O)CN1Cc2ccc(Cl)cc2[C@@]2(CCN(c3cncc4cc(NS(C)(=O)=O)c(F)cc34)C2=O)C1
CNC(=O)CN1C[C@]2(CCN(c3cncc4cc(NS(C)(=O)=O)c(F)cc34)C2=O)c2cc(Cl)ccc2C1=O
CS(=O)(=O)Nc1cc2cncc(NC(=O)Cc3cccc(Cl)c3)c2cc1F
CS(=O)(=O)Nc1cc2cncc(NC(=O)C3CN(S(=O)(=O)CC4(C#N)CC4)Cc4ccc(Cl)cc43)c2cc1F
CNC(=O)CN1Cc2ccc(Cl)cc2C(C(=O)Nc2cncc3cc(NS(C)(=O)=O)c(F)cc23)C1
CNC(=O)CN1CC(C(=O)Nc2cncc3cc(NS(C)(=O)=O)c(F)cc23)c2cc(Cl)ccc2C1=O
CS(=O)(=O)Nc1cc2cncc(N3CCC4(CN(S(=O)(=O)CC5(C#N)CC5)Cc5ccc(Cl)cc54)C3=O)c2cc1F
CNC(=O)CN1Cc2ccc(Cl)cc2C2(CCN(c3cncc4cc(NS(C)(=O)=O)c(F)cc34)C2=O)C1
CNC(=O)CN1CC2(CCN(c3cncc4cc(NS(C)(=O)=O)c(F)cc34)C2=O)c2cc(Cl)ccc2C1=O
Design Rationale:
Methanesulfonamido is well tolerated (EDJ-MED-be9e6f63-3 | MAT-POS-b4d6b7fc-2 | MAT-POS-b4d6b7fc-1) at C7 of the P1-isoquinoline although sulfonamide N-methylation (MAT-POS-22373164-1) results in about 6-fold reduction in potency. The designs in the submission address potential efflux due to the sulfonamide hydrogen bond donor by placing fluoro at C6 (there is precedent for this tactic; see Table 9 in J Med Chem 2015 58:2584–2608 https://doi.org/10.1021/jm501535r). There is uncertainty in the orientation of the methanesulfonamido substituent and I would recommend starting with Design 7 (3-chlorophenylphenylacetamide). The racemates for the chiral designs have been included in this submission.
Other Notes:
Protein-ligand complexes (P1788 A chain) were energy-minimized using Szybki (MMFF94S). The PDB file associated with this submission contains the following: [1] P1788 A chain protein structure [2] P1788 A chain crystallographic ligand (MAT-POS-dc2604c4-1) [3-9] Binding modes predicted for Designs 1-7.